New template and updated template for EUA requests for SARS-CoV-2 antibody tests

If your email program has trouble displaying this email, view as a webpage. COVID-19 Update: Serology EUA Templates for Test Developers Today, the U.S. Food and Drug Administration (FDA) posted two templates with recommendations on what to include in Emergency Use Authorization (EUA) requests or Pre-EUA submissions for serology tests. Template for Test Developers of Serology Tests that Detect or Correlate to Neutralizing Antibodies (New) Serology Template for Test Developers (Update) The FDA updated the template to add clarity throughout and provide recommendations regarding monitoring for and assessing the impact of new SARS-CoV-2 mutations and variants. These templates provide the FDA's current recommendations concerning what data and information should be submitted to the FDA in support of an EUA request or Pre-EUA submission for SARS-CoV-2 antibody tests. The templates are intended to help test developers provide validation data and other information to the FDA, but alternative approaches can be used. Download Templates Questions? If you have questions about the templates, please email COVID19DX@fda.hhs.gov.

Manage Subscriptions  |  Unsubscribe All  |  Help

This email was sent to ooseims.archieves@blogger.com using GovDelivery Communications Cloud on behalf of: U.S. Food and Drug Administration ·  10903 New Hampshire Ave · Silver Spring, MD ·  20993-0002 ·  1-888-INFO-FDA